Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses Armored RNA Technology to Cepheid for Diagnostic Assays

NEW YORK, April 11 (GenomeWeb News) - Cepheid has licensed technology for RNA standards and controls from Ambion Diagnostics for use in molecular diagnostic assays, Ambion said today.

 

Under the agreement, Cepheid gets non-exclusive rights to incorporate Ambion's Armored RNA technology into in vitro diagnostics. Ambion Diagnostics, a division of Ambion, will manufacture custom reagents for Cepheid, which will use them with its SmartCycler and GeneXpert platforms.

 

Armored RNA technology, invented by Ambion and Cenetron, helps to stabilize RNA by packaging it in bacteriophage coat proteins. A major application is the production of RNA controls and standards for viral assays. Cepheid plans to use the technology to develop diagnostic tests in the areas of infectious diseases and oncology.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.